

# SCIENTIFIC REPORTS



OPEN

## Proteinuria as a Therapeutic Target in Advanced Chronic Kidney Disease: a Retrospective Multicenter Cohort Study

Received: 14 August 2015

Accepted: 04 May 2016

Published: 20 May 2016


Chang-Hsu Chen<sup>1</sup>, Hon-Yen Wu<sup>2</sup>, Chieh-Li Wang<sup>3</sup>, Feng-Jung Yang<sup>4</sup>, Pei-Chen Wu<sup>5</sup>, Szu-Chun Hung<sup>6</sup>, Wei-Chih Kan<sup>7</sup>, Chung-Wei Yang<sup>8</sup>, Chih-Kang Chiang<sup>3</sup>, Jenq-Wen Huang<sup>3</sup> & Kuan-Yu Hung<sup>3</sup>

Current evidence of proteinuria reduction as a surrogate target in advanced chronic kidney disease (CKD) is incomplete due to lack of patient-pooled database. We retrospectively studied a multicenter cohort of 1891 patients who were enrolled in the nationwide multidisciplinary pre-end stage renal disease care program with a baseline glomerular filtration rate (GFR)  $< 45$  mL/min/1.73 m<sup>2</sup> and followed longitudinally to investigate the effect of the change in proteinuria on renal death (defined as composite of dialysis and death occurring before initiation of dialysis). The group with a change in proteinuria  $\leq 0.30$  g/g (n = 1261) had lower cumulative probabilities of renal death ( $p < 0.001$ ). In a linear regression model, a higher baseline proteinuria and a greater increase in proteinuria were associated with faster annual GFR decline. Cox's analysis showed that every 1 unit increase in natural log(baseline proteinuria, 10 g/g) and every 0.1 g/g increase in the change in proteinuria resulted in 67% (HR = 1.67, 95% CI: 1.46–1.91) and 1% (HR = 1.01, 95% CI: 1.01–1.01) greater risk of renal death respectively after adjusting for the effects of the other covariates. Our study provided a patient-based evidence to support proteinuria as a therapeutic target in advanced CKD.


The rapidly increasing incidence and prevalence of chronic kidney disease (CKD) have posed serious problems for global public health<sup>1,2</sup>. The impact of CKD on the burden of health resources includes increased risk of mortality, end-stage renal disease (ESRD), cardiovascular disease, mineral and bone disease, and other comorbidities<sup>2</sup>. The incidence and prevalence of ESRD in Taiwan are among the highest in the world<sup>3</sup>. An annual report of the Bureau of National Health Insurance (BNHI) in 2007 showed that 7.2% of health-care expenditure in Taiwan was used to provide treatment for patients with ESRD, although these patients accounted for only 0.23% of the local population<sup>4</sup>. According to national surveillance in Taiwan, the total prevalence of CKD was 11.93%, which was much higher than that in United States<sup>5</sup>, but only 3.54% of patients were aware of having CKD<sup>6</sup>. A strategy that prevents those with CKD from progressing to ESRD is mandatory for reducing the burden of ESRD.

Since 2002, the publication of a clinical practice guideline on CKD<sup>7</sup> by the National Kidney Foundation Kidney Disease Outcomes Quality Initiative (NKF KDOQI) has generated immense effects on research, clinical practice, and public health policy. In Taiwan, a nationwide CKD preventive program has been established with standard pre-ESRD multidisciplinary care for patients with stage 3b–5 CKD<sup>4</sup>. The program has been proven to be helpful in reducing the incidence of ESRD, mortality, and medical costs by means of a more effective diet and medical control according to the NKF KDOQI guidelines<sup>4,8,9</sup>.

<sup>1</sup>Division of Nephrology, Tungs' Taichung MetroHarbor Hospital, Taichung City, Taiwan. <sup>2</sup>Division of Nephrology, Far Eastern Memorial Hospital, New Taipei City, Taiwan. <sup>3</sup>Division of Nephrology, Department of Internal Medicine, National Taiwan University College of Medicine and Hospital, Taipei City, Taiwan. <sup>4</sup>Division of Nephrology, National Taiwan University Hospital Yun-Lin Branch, Yunlin County, Taiwan. <sup>5</sup>Division of Nephrology, Da Chien General Hospital, Miaoli County, Taiwan. <sup>6</sup>Division of Nephrology, Buddhist Tzu Chi Hospital Taipei Branch, New Taipei City, Taiwan. <sup>7</sup>Department of Nephrology, Chi Mei Medical Center, Tainan City, Taiwan. <sup>8</sup>Division of Nephrology, National Taiwan University Hospital Hsin-Chu Branch, Hsinchu City, Taiwan. Correspondence and requests for materials should be addressed to C.-K.C. (email: ckchiang@ntuh.gov.tw) or J.-W.H. (email: jenqwen@ntuh.gov.tw)



**Figure 1.** Overview of cohort formation.



**Figure 2.** Generalized additive models for determination the cut-off points of (a) baseline proteinuria\*; (b) change in proteinuria\*\*. \*The value of x-axis is transformed by natural log  $[10 \times (\text{baseline UPCr, g/g})]$ . \*\*The value of x-axis is transformed by  $\Delta\text{UPCr (g/g)} \times 10$ . Note:  $\text{logit}(p) = \text{natural log}(p/1 - p)$ , where  $p = \text{probability of renal death}$ . Abbreviations: UPCr, urine protein-to-creatinine ratio;  $\Delta\text{UPCr}$ , change in UPCr.

Proteinuria is an independent risk factor for progressive kidney function decline as well as all-cause mortality<sup>10–13</sup>. Medical treatment that reduces proteinuria seems to be renoprotective against glomerular filtration rate (GFR) decline<sup>14–19</sup>. Besides, evidences showed that multimodal regimen targeting at proteinuria reduction could effectively retard the progression of CKD<sup>20,21</sup>. Proteinuria has been advocated as a potential target for treatment in CKD<sup>22–24</sup>. However, because of various definitions of proteinuria reduction and outcome variables, one systemic review addressed the necessity of evaluation of pooled individual patient-level database<sup>25</sup>. Besides, few studies included patients with stage 5 CKD<sup>26–28</sup>. By using a large population of patients with advanced CKD with multi-hospital collaboration in Taiwan, the present study investigated the hypothesis that proteinuria reduction benefits renal outcomes.

## Results

The overview of cohort formation was shown in Fig. 1. Overall, 1891 participants with a mean age of 66 years and a mean baseline spot urine protein-to-creatinine ratio (UPCr) level of  $1.63 \pm 2.08$  g/g were included in this study. The mean level of change in UPCr ( $\Delta\text{UPCr}$ ) was  $0.26 \pm 2.06$  g/g and the mean annual GFR decline was  $-1.93 \pm 5.89$  mL/min/per 1.73 m<sup>2</sup> per year. The patients with diabetic nephropathy had higher baseline UPCr compared to non-diabetic patients ( $2.92 \pm 2.57$  vs.  $1.05 \pm 1.48$  g/g). By using generalized additive models (GAM), patients were stratified into a high proteinuria group (baseline UPCr  $> 1.04$  g/g) and a low proteinuria group (baseline UPCr  $\leq 1.04$  g/g) (Fig. 2a and Table 1). High proteinuria group had higher prevalence of diabetic nephropathy and hypertension and a lower baseline GFR. The mean age was younger, and this group exhibited faster GFR decline, higher mean arterial pressure (MAP).

Variable	Baseline UPCR ≤1.04 g/g (n=999)	Baseline UPCR >1.04 g/g (n=892)	P value
Age (years)	68 ± 13	64 ± 13	<0.001
Men	634 (63.5)	442 (49.6)	<0.001
Married	767 (76.8)	661 (74.1)	0.177
Educated*	296 (29.6)	268 (30.0)	0.098
Employed	302 (30.2)	306 (34.3)	0.058
Smoker	189 (18.9)	190 (21.3)	0.197
Alcohol	92 (9.2)	76 (8.5)	0.60
Diabetic nephropathy	126 (12.6)	466 (52.2)	<0.001
Comorbidity			
Diabetes	397 (39.7)	518 (58.1)	<0.001
Cardiovascular disease	174 (17.4)	154 (17.3)	0.93
Hypertension	744 (74.5)	730 (81.8)	<0.001
PCKD	24 (2.4)	11 (1.2)	0.060
Herbal medication use	70 (7.0)	78 (8.7)	0.160
Prescribed	29 (2.9)	35 (3.9)	0.22
Non-prescribed	46 (4.6)	46 (5.2)	0.58
≥3 antihypertensive agents	108 (10.8)	148 (16.6)	<0.001
RAS blockade use	445 (44.5)	405 (45.4)	0.71
Baseline characteristics			
CKD stage 3b	419 (41.9)	171 (19.2)	<0.001
CKD stage 4	434 (43.4)	403 (45.2)	0.46
CKD stage 5	146 (14.6)	318 (35.7)	<0.001
MAP (mmHg)	93.8 ± 12.2	98.4 ± 13.5	<0.001
BMI (kg/m <sup>2</sup> )	25.5 ± 4.2	25.7 ± 4.6	0.39
Hemoglobin (g/dL)	11.6 ± 2.0	10.8 ± 2.0	<0.001
Corrected calcium (mg/dL)	9.0 ± 0.6	8.9 ± 0.6	0.011
Phosphate (mg/dL)	3.8 ± 0.8	4.2 ± 0.8	<0.001
Albumin (g/dL)	4.3 ± 0.4	4.1 ± 0.5	<0.001
UPCR (g/g)	0.42 ± 0.29	2.99 ± 2.36	<0.001
GFR (mL/min/per 1.73 m <sup>2</sup> )	27.24 ± 10.09	20.49 ± 9.88	<0.001
Changes			
ΔMAP (mmHg)	-0.5 ± 14.4	-1.8 ± 15.9	0.059
ΔBMI (kg/m <sup>2</sup> )	-0.2 ± 1.6	-0.3 ± 1.8	0.31
ΔHemoglobin (g/dL)	0.0 ± 1.4	-0.5 ± 1.6	<0.001
ΔCorrected Ca (mg/dL)	0.00 ± 0.6	0.0 ± 0.7	0.165
ΔPhosphate (mg/dL)	0.0 ± 0.8	0.4 ± 1.1	<0.001
ΔAlbumin (g/dL)	-0.1 ± 0.4	-0.1 ± 0.4	0.83
ΔUPCR (g/g)	0.36 ± 1.11	0.15 ± 2.76	0.029
Interval of changes (months)	19.1 ± 8.3	16.5 ± 6.0	<0.001
Annual GFR change (mL/min/per 1.73 m <sup>2</sup> per year)	-0.07 ± 5.82	-4.01 ± 5.24	<0.001
Follow-up time (months)	34.6 ± 12.3	29.2 ± 11.7	<0.001
Composite renal death	88 (8.8)	279 (31.3)	<0.001
Mortality	28 (2.8)	32 (3.6)	0.33
Dialysis	60 (6.0)	247 (27.7)	<0.001

**Table 1. General characteristics stratified by baseline proteinuria.** Abbreviations: UPCR, urine protein-to-creatinine ratio; PCKD, polycystic kidney disease; RAS, renin-angiotensin system; CKD, chronic kidney disease; MAP, mean arterial pressure; BMI, body mass index; GFR, glomerular filtration rate; Δ, changes in each covariate (defined as the level during follow-up minus the baseline level). Note: Data are mean ± SD or frequency (%). \*Participant with at least junior high school education.

A multiple linear regression analysis was applied for the independent determinants of annual GFR change (Table 2). Polycystic kidney disease, baseline proteinuria and the use of prescribed herbal medication are the three major factors that had negative associations with annual GFR change (i.e., the more negative value of annual GFR change, the more rapid decline in GFR). There are other conditions with negative association, such as increases in phosphate level and UPCR at follow-up (i.e., positive values of Δphosphate and ΔUPCR). Conversely, increases

Covariate	Estimate $\pm$ standard error	p value
Intercept	1.38 $\pm$ 1.28	0.28
Baseline UPCR (per ln(10 g/g))	-1.59 $\pm$ 0.10	<0.001
$\Delta$ Hemoglobin	0.94 $\pm$ 0.08	<0.001
$\Delta$ Phosphate	-1.23 $\pm$ 0.13	<0.001
Baseline GFR	-0.17 $\pm$ 0.01	<0.001
Baseline hemoglobin	0.60 $\pm$ 0.07	<0.001
Baseline phosphate	-0.78 $\pm$ 0.18	<0.001
$\Delta$ Albumin (<-0.2 or >0.6 g/dL)	0.99 $\pm$ 0.24	<0.001
$\Delta$ UPCR (per 10 g/g)	-0.02 $\pm$ 0.01	<0.001
PCKD	-2.62 $\pm$ 0.84	0.002
Non-DM $\times$ Non-RAS blockade	0.71 $\pm$ 0.25	0.004
$\Delta$ BMI (<-0.4 or >2.4 kg/m <sup>2</sup> )	0.62 $\pm$ 0.23	0.007
Prescribed herbal medication use	-1.51 $\pm$ 0.62	0.015

**Table 2. Multiple linear regression analysis of the predictors associated with annual GFR change.**

$R_2 = 0.3183$ . Abbreviations: GFR, glomerular filtration rate; UPCR, urine protein-to-creatinine ratio;  $\Delta$ , changes in each covariate (defined as the level during follow-up minus the baseline level); PCKD, polycystic kidney disease; DM, diabetes mellitus; RAS, renin-angiotensin system; BMI, body mass index.

in hemoglobin and a condition when changes in albumin were above 0.6 g/dl or below -0.2 g/dl are the two most important factors that had beneficial associations.

To investigate the difference in clinical characteristics of patients with CKD with different changes in UPCR, we divided all patients into two groups by  $\Delta$ UPCR of 0.30 g/g after GAM analysis (Fig. 2b and Table 3). There was no significant difference in mean baseline UPCR, renin-angiotensin system (RAS) blockade, and interval between the two UPCR measurements. Patients in group of  $\Delta$ UPCR >0.30 g/g had fewer men, younger mean age, more hypertension, lower baseline GFR, and higher proportion of diabetic nephropathy and stage 5 CKD. They also presented increased MAP and phosphate level at follow-up (i.e., more positive values of  $\Delta$ MAP and  $\Delta$ phosphate). Besides, their annual GFR declined faster, their level of albumin decreased more (i.e., more negative values of  $\Delta$ albumin), and greater proportion of them suffered from renal death.

In total, 367 participants (19.6%) suffered from renal death in a mean follow-up time of  $32.0 \pm 12.3$  months. A Nelson-Aalen analysis revealed that the cumulative probabilities regarding renal death, mortality, and dialysis were lower in the low proteinuria group than those in the high proteinuria group (Fig. 3a-c). In another stratification with  $\Delta$ UPCR, the cumulative probabilities of renal death and dialysis were also lower in the patients with  $\Delta$ UPCR  $\leq 0.30$  g/g than those in the patients with  $\Delta$ UPCR >0.30 g/g (Fig. 4a-c). However, there was no significant difference in terms of mortality between the two groups.

A Cox's proportional hazards ratio analysis was used to determine the independent risk factors for renal death (Table 4). Every 1 unit increase in natural log(baseline proteinuria, 10 g/g) would result in a 67% increase in renal death risk (HR 1.67, 95% CI 1.46-1.91). Besides, every 0.1 g/g increases in  $\Delta$ UPCR resulted in 1% greater risk of renal death (HR 1.01, 95% CI 1.01-1.01). The two edges of age distribution (<46 and >72 years) also increases the risk. Among 154 participants aged <46 years, only one died and 46 underwent dialysis. Of 661 participants aged >72 years, 45 died and 76 initiated dialysis. Phosphate levels of 3.7-7.2 mg/dL, body mass index (BMI) <23.9 or >36.4 kg/m<sup>2</sup>, and albumin levels of 3.2-4.4 g/dL also contributed to increments in odds ratio of renal death. Only a few participants had phosphate levels >7.2 mg/dL ( $n = 7$ ), BMI >36.4 kg/m<sup>2</sup> ( $n = 40$ ), or albumin levels <3.2 g/dL ( $n = 32$ ).

## Discussion


In this study of an advanced CKD population, we demonstrated that high baseline proteinuria (UPCR >1.04 g/g) was associated with rapid GFR decline and also predicted renal death. Additionally, less increase of proteinuria ( $\Delta$ UPCR  $\leq 0.30$  g/g) was significantly associated with slower renal function decline and also predicted a lower probability of dialysis and mortality.

The Modification of Diet in Renal Disease (MDRD) study showed that high proteinuria >1.0 g/day was a predictor of renal progression<sup>29,30</sup>. By using GAM analysis, our study derived a consistent cut-off value to define a high-risk group in clinical practice. With the increment of baseline proteinuria, the rate of annual GFR decline and risk of renal death all increased. This is consistent with the previous literature that baseline proteinuria is almost linearly related to renal outcome<sup>23</sup>. Furthermore, one recent study showed that GFR decline was also strongly associated of the risk of ESRD and mortality<sup>31</sup>. In our study, baseline proteinuria is more strongly associated with renal progression and more predictive of renal death than GFR decline. One recent population-base cohort implied the similar concept by demonstrating that participants with heavy proteinuria but without overtly abnormal GFR had more rapid decline of kidney function than did those with moderately reduced GFR but mild proteinuria<sup>32</sup>.


Variable	$\Delta$ UPCR $\leq 0.30$ g/g (n = 1261)	$\Delta$ UPCR $> 0.30$ g/g (n = 630)	P value
Age	67 $\pm$ 13	65 $\pm$ 13	0.025
Men	754 (59.8)	322 (51.1)	<0.001
Married	962 (76.3)	466 (74.0)	0.28
Educated*	392 (31.1)	172 (27.3)	0.098
Employed	407 (32.3)	201 (31.9)	0.88
Smoker	259 (20.5)	120 (19.0)	0.47
Diabetic nephropathy	365 (28.9)	227 (36.0)	0.002
Comorbidity			
Diabetes	592 (46.9)	323 (51.3)	0.079
Cardiovascular disease	226 (17.9)	102 (16.2)	0.37
Hypertension	959 (76.1)	515 (81.7)	0.005
PCKD	24 (1.9)	11 (1.7)	0.86
Herbal medication use	98 (7.8)	50 (7.9)	0.93
$\geq 3$ antihypertensive agents	158 (12.5)	98 (15.6)	0.075
RAS blockade use	566 (44.9)	284 (45.1)	0.96
Baseline characteristics			
CKD stage 3b	445 (35.3)	145 (23)	<0.001
CKD stage 4	548 (43.5)	289 (45.9)	0.33
CKD stage 5	268 (21.3)	196 (31.1)	<0.001
MAP (mmHg)	96.1 $\pm$ 13.1	95.6 $\pm$ 12.8	0.42
BMI (kg/m <sup>2</sup> )	25.5 $\pm$ 4.3	25.6 $\pm$ 4.5	0.67
Hemoglobin (g/dL)	11.4 $\pm$ 2.1	10.8 $\pm$ 2.0	<0.001
Corrected calcium (mg/dL)	9.2 $\pm$ 0.6	9.1 $\pm$ 0.6	0.095
Phosphate (mg/dL)	3.9 $\pm$ 0.8	4.1 $\pm$ 0.8	<0.001
Albumin (g/dL)	4.3 $\pm$ 0.4	4.2 $\pm$ 0.4	0.013
UPCR (g/g)	1.66 $\pm$ 2.29	1.57 $\pm$ 1.58	0.38
GFR (mL/min/per 1.73 m <sup>2</sup> )	25.10 $\pm$ 10.54	21.96 $\pm$ 10.24	<0.001
Changes			
$\Delta$ MAP (mmHg)	-2.6 $\pm$ 14.9	1.9 $\pm$ 15.0	<0.001
$\Delta$ BMI (kg/m <sup>2</sup> )	-0.2 $\pm$ 1.7	-0.2 $\pm$ 1.8	0.56
$\Delta$ Hemoglobin (g/dL)	-0.2 $\pm$ 1.4	-0.1 $\pm$ 1.7	0.175
$\Delta$ Corrected calcium (mg/dL)	0.0 $\pm$ 0.6	-0.1 $\pm$ 0.7	0.092
$\Delta$ Phosphate (mg/dL)	0.1 $\pm$ 0.9	0.3 $\pm$ 1.2	0.002
$\Delta$ Albumin (g/dL)	-0.1 $\pm$ 0.4	-0.2 $\pm$ 0.4	<0.001
$\Delta$ UPCR (g/g)	-0.55 $\pm$ 1.35	1.89 $\pm$ 2.27	<0.001
Interval of changes (months)	17.7 $\pm$ 7.0	18.2 $\pm$ 8.0	0.26
Annual GFR change (mL/min/per 1.73 m <sup>2</sup> per year)	-1.58 $\pm$ 5.80	-2.62 $\pm$ 6.01	<0.001
Follow-up time (months)	32.5 $\pm$ 12.2	31.1 $\pm$ 12.6	0.015
Composite renal death	192 (15.2)	175 (27.8)	<0.001
Mortality	39 (3.1)	21 (3.3)	0.78
Dialysis	153 (12.1)	154 (24.4)	<0.001

**Table 3. Characteristics of participants stratified by level of change in proteinuria.** Abbreviations:  $\Delta$ , changes in each covariate (defined as the level during follow-up minus the baseline level); UPCR, urine protein-to-creatinine ratio; PCKD, polycystic kidney disease; RAS, renin-angiotensin system; MAP, mean arterial pressure; BMI, body mass index; GFR, glomerular filtration rate. Note: Data are mean  $\pm$  SD or frequency (%). \*Participant with at least junior high school education.

Proteinuria reduction and residual proteinuria are predictors of renal disease progression and ESRD<sup>18,23,33–35</sup>. Short-term changes in proteinuria predicted GFR decline rate in non-diabetic nephropathy<sup>34</sup>. In type 2 diabetic nephropathy, a post hoc study showed that the hazard ratio gradually decreased if more reduction in percent change in proteinuria was achieved<sup>23</sup>. This effect was independent of treatment-related blood pressure changes<sup>33</sup>. The protective effects of proteinuria reduction persisted in late stage of CKD<sup>26,28,36,37</sup>. For example, one study in Chinese patients with creatinine clearance of 20 to 70 mL/min/1.73 m<sup>2</sup> showed a significant correlation between the extent of proteinuria reduction and GFR decline<sup>26</sup>. However, only one of these studies enrolled stage 5 CKD<sup>28</sup> and the ages of these study populations were younger than ours. Moreover, one study in non-diabetic nephropathy found that participants with higher residual proteinuria at 3 month had faster rate of GFR decline<sup>34</sup>. Similarly, residual proteinuria  $< 0.5$  g/day at 6 months had lowest hazard ratio of renal events in diabetic nephropathy<sup>23</sup>.



**Figure 3.** The Nelson–Aalen estimates for the cumulative hazard rates between the two groups stratified by baseline proteinuria (1.04 g/g). The patients with baseline UPPCR  $\geq 1.04$  g/g had a higher hazard rate for composite renal death (A,  $p < 0.001$ ), mortality (B,  $p = 0.029$ ), and dialysis (C,  $p < 0.001$ ).



**Figure 4.** The Nelson–Aalen estimates for the cumulative hazard rates between the two groups stratified by change of proteinuria ( $\Delta$ UPCR 0.3 g/g). The patients with  $\Delta$ UPCR  $> 0.3$  g/g had a higher hazard rate for composite renal death (A,  $p < 0.001$ ) and dialysis (C,  $p < 0.001$ ). However, the mortality was not significantly different between the two groups (B,  $p = 0.515$ ).

Covariate	Estimate $\pm$ se	Wald Chi-Square	Hazard ratio	95% Confidence interval	$p$ value
Baseline hemoglobin	$-0.088 \pm 0.034$	$-0.265$	0.92	0.86–0.98	0.087
Baseline UPPCR* (per $\ln(10$ g/g))	$0.510 \pm 0.069$	7.436	1.67	1.46–1.91	$< 0.001$
Baseline GFR	$-0.273 \pm 0.031$	$-8.858$	0.76	0.72–0.81	$< 0.001$
Baseline GFR $\times$ time to renal death	$0.005 \pm 0.001$	4.575	1.00	1.00–1.01	$< 0.001$
Annual GFR decline	$-0.359 \pm 0.047$	$-7.625$	0.70	0.72–0.81	$< 0.001$
Annual GFR decline $\times$ time to renal death	$0.005 \pm 0.002$	3.181	1.01	1.00–1.01	0.002
$\Delta$ UPCR (per 10 g/g)	$0.011 \pm 0.002$	5.577	1.01	1.01–1.01	$< 0.001$
Men	$0.518 \pm 0.116$	4.487	1.68	1.34–2.10	$< 0.001$
Age ( $< 46$ or $> 72$ years)	$-0.471 \pm 0.108$	4.380	1.60	1.30–1.98	$< 0.001$
Baseline BMI ( $< 23.9$ or $> 36.4$ kg/m <sup>2</sup> )	$0.397 \pm 0.108$	3.657	1.49	1.20–1.84	$< 0.001$
Baseline phosphate (3.7–7.2 mg/dL)	$0.429 \pm 0.136$	3.149	1.53	1.18–2.00	0.002
Baseline albumin (3.2–4.4 g/dL)	$0.255 \pm 0.118$	2.169	1.29	1.02–1.63	0.030
Educated**	$0.252 \pm 0.121$	2.090	1.29	1.02–1.63	0.037
Herbal medication use	$0.308 \pm 0.167$	1.846	1.36	0.98–1.89	0.065

**Table 4.** Predictors of composite renal death by Cox’s model. Goodness-of-fit assessment: Adjusted generalized  $R^2 = 0.3669 > 0.15$  and concordance = 0.89  $> 0.7$  (se = 0.016) indicated a very good fit. Abbreviations: se, standard error; UPPCR, urine protein-to-creatinine ratio; GFR, glomerular filtration rate;  $\Delta$ UPPCR, change in UPPCR (defined as the level at follow-up minus the baseline level); BMI, body mass index. \*The value of baseline UPPCR was natural log-transformed in regression analysis for making its distribution more symmetric. \*\*Educated = 1 for participant with at least junior high school education, 0 otherwise.

Reducing proteinuria to  $<1$  g/day or  $<0.5$  g/day had been proposed as the goal of treatment<sup>19,21,34,38</sup>. Because of our study design, we were unable to demonstrate the effect of residual proteinuria. However, our study further extended the beneficial effect of proteinuria reduction to population of older and more advanced CKD.

Comparing to baseline proteinuria, the effects of changes in proteinuria were smaller on both GFR decline and renal death. Participants with higher baseline proteinuria reflected more severe degree of nephron dysfunction and damage<sup>22</sup>. In one study, although the low baseline proteinuria group had less proteinuria reduction and benefited less from the treatment, their renal outcome is better comparing to the overt proteinuria group<sup>35,39</sup>. Another study concluded that baseline proteinuria is the best independent predictor of disease progression and ESRD in non-diabetic proteinuric CKD<sup>40</sup>. However, a worsening proteinuria invariably predicts poor outcome<sup>19,22</sup>. Instead of precluding the benefit of proteinuria reduction, our finding supported the importance of early detection and referral of CKD before progression to overt proteinuria<sup>41</sup>.

In contrast to previous literature<sup>42,43</sup>, diabetes mellitus (DM) did not appear to be an independent risk factor in terms of GFR decline and renal death in our study. The effect of DM may have been embedded in some highly correlated factors, such as baseline UPCR and  $\Delta$ UPCR, and became insignificant in multiple regression analysis. In addition, non-diabetic patients without using RAS blockade in our study were associated with better renal progression in the linear regression analysis. Recent meta-analyses had shown that RAS blockade was renoprotective in diabetic patients<sup>44,45</sup>, and KDIGO guideline<sup>46</sup> also strongly recommended RAS blockade use in non-diabetic patients with CKD and severely increased proteinuria. Although less than a half of our participants received RAS blockade, we found that more patients were classified into  $\Delta$ UPCR  $\leq 0.3$  g/g group, which might inferred the effectiveness of multidisciplinary care in controlling proteinuria. Besides, one study showed that still a substantial number of participants with diabetes and nephropathy treated with losartan had no reduction in proteinuria<sup>33</sup>. This may explain why our participants who could not achieve control of proteinuria had more often diabetic nephropathy. Use of RAS blockade in advanced CKD was considered safe in post hoc analyses of two randomized control trials and two trials in Chinese population<sup>26,28,36,37</sup>. However, the mean ages of these trials were younger than ours and current evidence of RAS blockade use in elderly CKD patients was still limited<sup>47</sup>. One recent study with a small number of elderly patients with CKD also showed that discontinuation of RAS blockade delayed the onset of dialysis<sup>48</sup>. Therefore, monitoring renal function is mandatory when using RAS blockade in patients with advanced CKD. Other modifiable risk factors including hemoglobin, phosphate level, BMI, and blood pressure were also important in predicting renal death (see Supplementary Discussion). These results implied the goals and directions of multidisciplinary care in advanced CKD patients.

The strength of our study is that our participants received standard multidisciplinary care based on the NKF KDOQI guidelines instead of specific drug therapy, as proposed by previous literature<sup>49</sup>. Our cohort was older and we enrolled a substantial number of patients with stage 5 CKD. The mean annual GFR decline rate in our cohort was below most of the studies in CKD populations<sup>46</sup>, and two-thirds of our participants had stable to reduced proteinuria during study period. By using a patient-level pooled cohort with standardized care during a long period, as proposed by the previous literature<sup>25</sup>, our study provided relatively strong evidence for surrogacy.

There were several limitations in our study. First, due to retrospective study design, we were unable to adjust specific interventions and pharmacotherapy other than RAS blockade or to clarify the characteristics that lead to different degrees of proteinuria reduction under same treatment strategy. Second, our study population comprised exclusively of Taiwanese with advanced CKD who were referred to multi-discipline care. For examples, patients with more rapid progression who are unable to collect subsequent proteinuria were excluded. Selection bias might exist. Third, the MDRD equation was developed based on younger Caucasian subjects (aged  $50.6 \pm 12.7$  years)<sup>46</sup> and it may not correctly estimate the GFR among our patients. Moreover, one study showed that indirect formulas failed to provide reliable estimation of renal function changes over time<sup>50</sup>. Fourth, we used urine total protein instead of urine albumin, which is proposed by KDIGO guideline as a more sensitive marker<sup>46</sup>. However, urinary albumin and total protein perform equally in prediction of renal outcomes and mortality in patients with CKD<sup>46,51,52</sup>, and measuring urinary albumin is more costly than measuring total protein<sup>46,51</sup>. Besides, UPCR was significantly correlated with 24-hour urine protein excretion and highly predictive for disease progression<sup>53</sup>. Therefore, our program used UPCR as a marker during long-term surveillance. Fifth, patients with CKD may have diverse pattern of GFR trajectory<sup>54</sup>, and determination of renal progression by measuring two GFR in a time period may less accurately estimate the slope of GFR decline. Besides, serial measurement of concurrent time-varying proteinuria, GFR and associated clinical condition might be needed.

In summary, this multicenter retrospective study including participants with advanced CKD under multidisciplinary care in nephrology clinics showed that high proteinuria was associated with rapid GFR decline and also predicted renal death. The cut-off level of UPCR 1.04 g/g could be used in clinical practice to classify a high-risk group. Additionally, proteinuria reduction was significantly associated with slower renal function decline and also predicted risk of dialysis. To aim at improving renal outcome, the clinician can adjust the treatment policy to reduce proteinuria as much as possible. Our study supported the concept that proteinuria is a therapeutic target in patients with advanced CKD.

## Methods

**Study Design and Population.** This is a retrospective cohort study conducted in six collaborative hospitals in Taiwan from 2008 to 2011. Patients who joined the nationwide pre-ESRD care program were enrolled. The GFR was estimated by using the MDRD study equation<sup>7</sup>:  $GFR = 186 \times \text{Serum Cre}^{-1.154} \times \text{Age}^{-0.203} \times (0.742 \text{ if female})$ . We selected patients aged above 18 years with a baseline GFR  $<45$  mL/min/per  $1.73 \text{ m}^2$  and at least two measurements of serum creatinine. We further excluded patients with less than two measurements of urine protein excretion (defined as spot urine protein-to-creatinine ratio, UPCR [g/g]). Patients with the interval of separate proteinuria measurements less than 9 months were also excluded. The severity of CKD was then staged based on the NKF KDOQI clinical practice guidelines<sup>7</sup>. The study was conducted in accordance with the Declaration

of Helsinki and was approved by the medical ethics review boards of Tungs' Taichung MetroHarbor Hospital, Far Eastern Memorial Hospital, National Taiwan University College of Medicine and Hospital and Da Chien General Hospital. Besides, waiver of the consent requirement was approved due to retrospective design and non-disclosure of patient- information.

**Pre-ESRD Care Program.** The pre-ESRD care program in Taiwan included standardized interventions and multidisciplinary care that followed the NKF KDOQI guidelines<sup>7</sup> and reimbursement policy of the BNHI. The members of this program included nephrologists, nurses, and dieticians, and integrated individual lectures focusing on nutrition, lifestyle, nephrotoxin avoidance, dietary principles, and pharmacological regimens as well as clinical evaluation and laboratory examinations were provided<sup>4,8</sup>. The criteria for dialysis initiation indicated by the BNHI included serum creatinine level  $\geq 8$  mg/dL or GFR  $< 5$  mL/min/per 1.73 m<sup>2</sup>; or serum creatinine level  $\geq 6$  mg/dL or GFR  $\leq 15$  mL/min/per 1.73 m<sup>2</sup> with the presence of one or more uremic symptoms that threaten life or impair quality of life<sup>8,9</sup>.

**Patient Characteristics and Description of the Data Set.** Demographics collected through medical records and registry data in each hospital included age; sex; employment status; education; smoking habits; drinking and betel nut use; original cause of renal failure; BMI; MAP; biochemical measurements including hemoglobin, serum albumin, calcium, phosphate, and UPCR; comorbidity history; and antihypertensive drugs. Diabetic nephropathy was defined as UPCR  $\geq 0.5$  g/g in patients with diabetes mellitus without any other cause of renal failure.

**Outcome Assessment.** Two primary outcomes were selected from our analysis. First, renal death was defined as the composite of initiation of dialysis and mortality (deaths occurring before initiating dialysis). Second, annual GFR change was estimated as the slope of a linear model including two GFR measurements, determined in mL/min/per 1.73 m<sup>2</sup> per year. The change in covariates ( $\Delta$  value) was defined as the value in follow-up minus baseline value of each parameter. A repeated-measures analysis was not used to assess changes during follow-up because the times of follow-up measurements varied across the patients.

**Statistical Analysis.** A statistical analysis was performed using the IBM SPSS Statistics 21 software (IBM Corporation, Armonk, NY, United States) and the R 3.0.2 software (The R Foundation for Statistical Computing, Vienna, Austria). In statistical testing, a two-sided  $p$  value  $\leq 0.05$  was considered statistically significant. The distributional properties of continuous variables were expressed as mean (standard deviation, SD), categorical variables were presented by frequency and percentage, and the cumulative hazard rates of survival outcomes were estimated by the Nelson-Aalen method.

GAMs<sup>55</sup> were fitted to determine the appropriate cut-off points of baseline UPCR and  $\Delta$ UPCR for classifying patients into different groups. GAMs were fitted to detect nonlinear effects of continuous covariates and to identify appropriate cut-off point(s) for discretizing a continuous covariate, if necessary, during the stepwise variable selection procedure. Computationally, the *vgam* function (with the default values of smoothing parameters) of the VGAM package<sup>56,57</sup> was used to fit GAMs for continuous and binary responses in R. Finally, the statistical tools of regression diagnostics for verification of proportional hazards assumption, residual analysis, detection of influential cases, and check of multicollinearity were applied to discover any model or data problems. The values of variance inflating factor (VIF)  $\geq 10$  in continuous covariates or  $\geq 2.5$  in categorical covariates indicate the occurrence of the multicollinearity problem among some of the covariates in the fitted regression model. If the required proportional hazards assumption was not satisfied in some covariates, the Cox's proportional hazards model would be fitted to the long-form data with added interaction terms between survival time and the covariate(s) violating the proportional hazards assumption.

In univariate analysis, the two-sample  $t$  test, Wilcoxon rank-sum test, chi-square test, and Fisher's exact test (if the expected values in any of the cells of a contingency table were  $< 5$ ) were used to examine the differences in the distributions of continuous variables and categorical variables within groups stratified by UPCR as well as  $\Delta$ UPCR. Next, a multivariate analysis was conducted by fitting the linear regression model and Cox's proportional hazards model to estimate the effects of risk factors, prognostic factors, or predictors on annual GFR change, occurrence of renal death, and time to renal death, respectively.

## References

- Lysaght, M. J. Maintenance dialysis population dynamics: current trends and long-term implications. *J Am Soc Nephrol* **13** Suppl 1, S37–40 (2002).
- Jha, V., Wang, A. Y. & Wang, H. The impact of CKD identification in large countries: the burden of illness. *Nephrol Dial Transplant* **27** Suppl 3, iii32–38 (2012).
- Hwang, S. J. *et al.* Increased risk of mortality in the elderly population with late-stage chronic kidney disease: a cohort study in Taiwan. *Nephrol Dial Transplant* **23**, 3192–3198 (2008).
- Chen, Y. R. *et al.* Effectiveness of multidisciplinary care for chronic kidney disease in Taiwan: a 3-year prospective cohort study. *Nephrol Dial Transplant* **28**, 671–682 (2013).
- Wen, C. P. *et al.* All-cause mortality attributable to chronic kidney disease: a prospective cohort study based on 462 293 adults in Taiwan. *The Lancet* **371**, 2173–2182 (2008).
- Levin, A. & Djurdjev, O. On being better kidney doctors: understanding trajectories, probabilities, predictability, and people. *Am J Kidney Dis* **59**, 475–477 (2012).
- National Kidney, F. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. *Am J Kidney Dis* **39**, S1–266 (2002).
- Wu, I. W. *et al.* Multidisciplinary predialysis education decreases the incidence of dialysis and reduces mortality—a controlled cohort study based on the NKF/DOQI guidelines. *Nephrol Dial Transplant* **24**, 3426–3433 (2009).
- Wei, S. Y. *et al.* Chronic kidney disease care program improves quality of pre-end-stage renal disease care and reduces medical costs. *Nephrology (Carlton)* **15**, 108–115 (2010).

10. Ishani, A. *et al.* Association of single measurements of dipstick proteinuria, estimated glomerular filtration rate, and hematocrit with 25-year incidence of end-stage renal disease in the multiple risk factor intervention trial. *J Am Soc Nephrol* **17**, 1444–1452 (2006).
11. Hemmelgarn, B. R. *et al.* Relation between kidney function, proteinuria, and adverse outcomes. *JAMA* **303**, 423–429 (2010).
12. Matsushita, K. *et al.* Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. *Lancet* **375**, 2073–2081 (2010).
13. Ruggenenti, P. *et al.* Proteinuria predicts end-stage renal failure in non-diabetic chronic nephropathies. The “Gruppo Italiano di Studi Epidemiologici in Nefrologia” (GISEN). *Kidney Int Suppl* **63**, S54–57 (1997).
14. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. *Lancet* **349**, 1857–1863 (1997).
15. Brenner, B. M. *et al.* Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. *N Engl J Med* **345**, 861–869 (2001).
16. Lewis, E. J. *et al.* Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. *N Engl J Med* **345**, 851–860 (2001).
17. Agodoa, L. Y. *et al.* Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. *JAMA* **285**, 2719–2728 (2001).
18. Lea, J. *et al.* The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension. *Arch Intern Med* **165**, 947–953 (2005).
19. Ruggenenti, P., Schieppati, A. & Remuzzi, G. Progression, remission, regression of chronic renal diseases. *Lancet* **357**, 1601–1608 (2001).
20. Ruggenenti, P., Brenner, B. M. & Remuzzi, G. Remission achieved in chronic nephropathy by a multidrug approach targeted at urinary protein excretion. *Nephron* **88**, 254–259 (2001).
21. Ruggenenti, P. *et al.* Role of remission clinics in the longitudinal treatment of CKD. *J Am Soc Nephrol* **19**, 1213–1224 (2008).
22. Ruggenenti, P., Cravedi, P. & Remuzzi, G. Mechanisms and treatment of CKD. *J Am Soc Nephrol* **23**, 1917–1928 (2012).
23. de Zeeuw, D. *et al.* Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. *Kidney Int* **65**, 2309–2320 (2004).
24. Levey, A. S. *et al.* Proteinuria as a surrogate outcome in CKD: report of a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. *Am J Kidney Dis* **54**, 205–226 (2009).
25. Stoycheff, N. *et al.* Early change in proteinuria as a surrogate outcome in kidney disease progression: a systematic review of previous analyses and creation of a patient-level pooled dataset. *Nephrol Dial Transplant* **26**, 848–857 (2011).
26. Hou, F. F. *et al.* Efficacy and safety of benazepril for advanced chronic renal insufficiency. *N Engl J Med* **354**, 131–140 (2006).
27. de Goeij, M. C. *et al.* Proteinuria as a risk marker for the progression of chronic kidney disease in patients on predialysis care and the role of angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker treatment. *Nephron Clin Pract* **121**, c73–82 (2012).
28. Ruggenenti, P., Perna, A. & Remuzzi, G. Gruppo Italiano di Studi Epidemiologici in, N. ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results. Ramipril Efficacy in Nephropathy. *J Am Soc Nephrol* **12**, 2832–2837 (2001).
29. Hunsicker, L. G. *et al.* Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study. *Kidney Int* **51**, 1908–1919 (1997).
30. Peterson, J. C. *et al.* Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. *Ann Intern Med* **123**, 754–762 (1995).
31. Coresh, J. *et al.* Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality. *JAMA* **311**, 2518–2531 (2014).
32. Turin, T. C. *et al.* Proteinuria and rate of change in kidney function in a community-based population. *J Am Soc Nephrol* **24**, 1661–1667 (2013).
33. Eijkelkamp, W. B. *et al.* Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. *J Am Soc Nephrol* **18**, 1540–1546 (2007).
34. Ruggenenti, P., Perna, A., Remuzzi, G. & Investigators, G. G. Retarding progression of chronic renal disease: the neglected issue of residual proteinuria. *Kidney Int* **63**, 2254–2261 (2003).
35. Jafar, T. H. *et al.* Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. *Kidney Int* **60**, 1131–1140 (2001).
36. Remuzzi, G. *et al.* Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: a post hoc analysis of the RENAAL trial results. *J Am Soc Nephrol* **15**, 3117–3125 (2004).
37. Hou, F. F. *et al.* Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency. *J Am Soc Nephrol* **18**, 1889–1898 (2007).
38. Imai, E. *et al.* Reduction and residual proteinuria are therapeutic targets in type 2 diabetes with overt nephropathy: a post hoc analysis (ORIENT-proteinuria). *Nephrol Dial Transplant* **28**, 2526–2534 (2013).
39. Kent, D. M. *et al.* Progression risk, urinary protein excretion, and treatment effects of angiotensin-converting enzyme inhibitors in nondiabetic kidney disease. *J Am Soc Nephrol* **18**, 1959–1965 (2007).
40. Ruggenenti, P., Perna, A., Mosconi, L., Pisoni, R. & Remuzzi, G. Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. “Gruppo Italiano di Studi Epidemiologici in Nefrologia” (GISEN). *Kidney Int* **53**, 1209–1216 (1998).
41. James, M. T., Hemmelgarn, B. R. & Tonelli, M. Early recognition and prevention of chronic kidney disease. *Lancet* **375**, 1296–1309 (2010).
42. Haroun, M. K. *et al.* Risk factors for chronic kidney disease: a prospective study of 23,534 men and women in Washington County, Maryland. *J Am Soc Nephrol* **14**, 2934–2941 (2003).
43. Taal, M. W. & Brenner, B. M. Predicting initiation and progression of chronic kidney disease: Developing renal risk scores. *Kidney Int* **70**, 1694–1705 (2006).
44. Vejakama, P. *et al.* Reno-protective effects of renin-angiotensin system blockade in type 2 diabetic patients: a systematic review and network meta-analysis. *Diabetologia* **55**, 566–578 (2012).
45. Wu, H. Y. *et al.* Comparative effectiveness of renin-angiotensin system blockers and other antihypertensive drugs in patients with diabetes: systematic review and bayesian network meta-analysis. *BMJ* **347**, f6008 (2013).
46. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. *Kidney int suppl* **3**, 1–150 (2013).
47. O’Hare, A. M. *et al.* Current guidelines for using angiotensin-converting enzyme inhibitors and angiotensin II-receptor antagonists in chronic kidney disease: is the evidence base relevant to older adults? *Ann Intern Med* **150**, 717–724 (2009).
48. Ahmed, A. K., Kamath, N. S., El Kossi, M. & El Nahas, A. M. The impact of stopping inhibitors of the renin-angiotensin system in patients with advanced chronic kidney disease. *Nephrol Dial Transplant* **25**, 3977–3982 (2010).
49. Karalliedde, J. & Viberti, G. Proteinuria in diabetes: bystander or pathway to cardiorenal disease? *J Am Soc Nephrol* **21**, 2020–2027 (2010).
50. Gaspari, F. *et al.* The GFR and GFR decline cannot be accurately estimated in type 2 diabetics. *Kidney Int* **84**, 164–173 (2013).

51. Methven, S. *et al.* Comparison of urinary albumin and urinary total protein as predictors of patient outcomes in CKD. *Am J Kidney Dis* **57**, 21–28 (2011).
52. Wu, M. T. *et al.* Albuminuria, proteinuria, and urinary albumin to protein ratio in chronic kidney disease. *J Clin Lab Anal* **26**, 82–92 (2012).
53. Ruggenenti, P., Gaspari, F., Perna, A. & Remuzzi, G. Cross sectional longitudinal study of spot morning urine protein:creatinine ratio, 24 hour urine protein excretion rate, glomerular filtration rate, and end stage renal failure in chronic renal disease in patients without diabetes. *BMJ* **316**, 504–509 (1998).
54. Li, L. *et al.* Longitudinal progression trajectory of GFR among patients with CKD. *Am J Kidney Dis* **59**, 504–512 (2012).
55. Hastie, T. & Tibshirani, R. *Generalized additive models*. 1st edn, (Chapman and Hall, 1990).
56. Yee, T. W. & Wild, C. J. Vector Generalized Additive Models. *JR Stat Soci, Series B* **58**, 481–493 (1996).
57. Yee, T. W. *VGAM: Vector Generalized Linear and Additive Models. R package version 1.0-0.* (2015). Available at: <http://CRAN.R-project.org/package=VGAM>. (Accessed: 4th November 2015).

## Acknowledgements

We gratefully thank Dr Fu-Chang Hu for his valuable advice on statistic analysis. The study was granted by National Taiwan University College of Medicine and Hospital, Taipei, Taiwan (NTUH.102-S2124). The funders had no influence on design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript.

## Author Contributions

J.-W.H. designed the experiments. C.-H.C. and J.-W.H. analyzed the data and contributed to the writing of the manuscript. C.-H.C., H.-Y.W., P.-C.W., C.-L.W., F.-J.Y., C.-W.Y. and C.-K.C. enrolled the patients. W.-C.K. and S.-C.H. contributed analysis tools. The study was supervised by K.-Y.H. All authors participated in the critical revision of the article and approved the final version.

## Additional Information

**Supplementary information** accompanies this paper at <http://www.nature.com/srep>

**Competing financial interests:** The authors declare no competing financial interests.

**How to cite this article:** Chen, C.-H. *et al.* Proteinuria as a Therapeutic Target in Advanced Chronic Kidney Disease: a Retrospective Multicenter Cohort Study. *Sci. Rep.* **6**, 26539; doi: 10.1038/srep26539 (2016).



This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>